RxDoctor Payments Data

Brian Oconnor, MD

Addiction Medicine · Woburn, MANPI 1912991522

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $44,395 of the $50,534 with a category attached, or 87.9%. Alkermes, Inc. accounts for 99.5% of it on its own, with 3 other manufacturers making up the rest. Reporting peaked in 2019 at $44,275 and has fallen 99.8% since, to $72 in 2025. Among addiction medicine clinicians in MA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$50,534in general payments, 2019–2025

Across 84 payments — averaging $601.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alkermes, Inc.$50K
  • Braeburn Inc.$132
  • Indivior Inc.$114
  • Irhythm Technologies, Inc.$24

What the payments were for

  • Speaking & faculty fees$44,39588%
  • Travel & lodging$4,2248%
  • Food & beverage$1,9114%
  • Education$50%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$50,534 in reported general payments places this provider in the 95th percentile of 57 addiction medicine providers in Massachusetts.

See all addiction medicine providers in Massachusetts

Medicare billing

Part B allowed, 2024
$173,564
Medicare patients
129
Services billed
2,186

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VivitrolNaltrexone Microspheres25$43,287
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl308$32,634
SuboxoneBuprenorphine Hcl/Naloxone Hcl28$15,226
Buprenorphine Hcl52$1,366
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine39$1,091
Acamprosate Calcium13$1,090
Clonidine Hcl33$417
Gabapentin36$354
Lorazepam45$294
Quetiapine Fumarate28$215
Alprazolam39$203
Escitalopram Oxalate14$195
Lamotrigine13$159
Diazepam13$158
Venlafaxine Hcl ErVenlafaxine Hcl12$86

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Alkermes, Inc.Vivitrol$50,265$43,28725 claims
Indivior Inc.Suboxone$114$15,22628 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 57 addiction medicine providers in Massachusetts.

Other addiction medicine in Woburn

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →